Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk’s obesity injection Wegovy and diabetes counterpart Ozempic.
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk’s obesity injection Wegovy and diabetes counterpart Ozempic.
About the Author
Previous Post
Next Post
Leave a Reply
Latest News
Stay Connected
Categories
Business Health India Politics Science Sports Technology Uncategorized World
Tags
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
